Journal article
Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer
JCO precision oncology, Vol.5(5), pp.1530-1539
2021
DOI: 10.1200/PO.21.00210
PMCID: PMC8492377
PMID: 34622117
Abstract
PURPOSE With the introduction of precision medicine, treatment options for non-small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the University of Kentucky (UK) implemented a statewide MTB in January 2017. We wanted to test the impact of UK MTB review on overall survival in Appalachian and other regions in Kentucky. METHODS We performed a case-control study of Kentucky patients newly diagnosed with non-small-cell lung cancer between 2017 and 2019. Cases were reviewed by the UK MTB and were compared with controls without UK MTB review. Controls were identified from the Kentucky Cancer Registry and propensity-matched to cases. The primary end point was the association between MTB review and overall patient survival. RESULTS Overall, 956 patients were included, with 343 (39%) residing in an Appalachian region. Seventy-seven (8.1%) were reviewed by the MTB and classified as cases. Cox regression analysis showed that poorer survival outcome was associated with lack of MTB review (hazard ratio [HR] = 8.61; 95% CI, 3.83 to 19.31; P < .0001) and living in an Appalachian region (hazard ratio = 1.43; 95% CI, 1.17 to 1.75; P = .004). Among individuals with MTB review, survival outcomes were similar regardless of whether they lived in Appalachia or other parts of Kentucky. CONCLUSION MTB review is an independent positive predictor of overall survival regardless of residence location. MTBs may help overcome some health disparities for disadvantaged populations.
Details
- Title: Subtitle
- Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer
- Creators
- Bin Huang - Markey Cancer CenterQuan Chen - Markey Cancer CenterDerek Allison - University of KentuckyRiham El Khouli - University of KentuckyKeng Hee Peh - University of KentuckyJames Mobley - University of KentuckyAbigail Anderson - Markey Cancer CenterEric B. Durbin - Markey Cancer CenterDonald Goodin - New England Baptist HospitalJohn L. Villano - University of KentuckyRachel W. Miller - University of KentuckySusanne M. Arnold - University of KentuckyJill M. Kolesar - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- JCO precision oncology, Vol.5(5), pp.1530-1539
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1200/PO.21.00210
- PMID
- 34622117
- PMCID
- PMC8492377
- ISSN
- 2473-4284
- eISSN
- 2473-4284
- Number of pages
- 10
- Grant note
- AstraZeneca Merck Sharp Dohme; Merck & Company Nektar Regeneron Exelixis National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Genentech; Roche Holding Ohio State University
- Language
- English
- Date published
- 2021
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695790402771
Metrics
5 Record Views